In a fitting coda to 2025, Tuesday’s market looked less like a grand finale and more like a dress rehearsal for 2026: stocks near records, AI titans and GLP‑1 champions still commanding the marquee, and a supporting cast of tariffs, deficits, metals…
In all, the final Monday of 2025 looked less like the start of a new narrative and more like a tidy epilogue: investors trimming winners, testing how far tariffs and higher real rates can bend the expansion without breaking it, and quietly…
Wall Street tiptoed into the final holiday stretch with a Santa Claus rally that felt more like a well‑tailored cashmere sweater than an ugly Christmas jumper: comfortable but not euphoric. Major U.S. indexes ground higher over the week ending Friday, December 26,…
Wall Street tiptoed into the Christmas break with its party hat still firmly on, as major indexes notched fresh records or near-record closes in a holiday‑shortened session that felt more champagne than coal. In all, Christmas Eve gave investors what they wanted…
Wall Street tiptoed into the holiday break on Tuesday with the air of a market that has already opened its presents and is now just admiring the wrapping paper. Stocks drifted rather than surged, but under the surface, big tech, nuclear hopefuls…
Wall Street opened the final Christmas week of 2025 in a festive mood, with equities drifting higher in to record territory as if trying on a Santa rally for size without quite committing to the full costume, however the smalls seem to…
Wall Street investors wrapped the week ending Friday, December 19, 2025 with dreams of sugarplums and a Santa Rally in their holiday minded heads & looking like it had just survived a very expensive group therapy session: growth darlings, rate‑sensitive cyclicals, and…
U.S. stocks advanced Thursday as investors toasted cooler inflation, lower yields and yet another tech-led melt-up, suggesting Santa is at least circling the mall parking lot even if he has not walked in yet. Risk assets climbed despite softer precious metals and…
Wall Street limped into the midweek close on Wednesday with the swagger of a champion and the posture of someone who just read their margin statement. Tech led a broad retreat, AI darlings finally discovered that debt still has a cost, and…
GeoVax’s (NASDAQ: GOVX) recent appearance in the British Journal of Haematology increasingly resembles the deliberate, early‑stage build‑out of a meaningful new franchise rather than a one‑off academic mention of a new immunotherapy franchise, now reinforced by fresh patent news from the U.S.…
